Crémieux
Crémieux
ADA-1,00%
Eli Lilly just showed that you can lose tons of fat while barely losing any muscle using their activin type-II receptor inhibitor, bimagrumab. We are approaching a golden era of weight loss, where everyone can easily be muscular and skinny. Prepare for hordes of hot Americans.
Gallery 1
The semaglutide-only weight loss results also speak against the lie that GLP-1RAs cause excess lean mass loss, as the proportion lost was comparable to typical non-GLP-1RA weight loss. To learn more, check out the update I just made on this article:
Reporting on this result from the ADA 2025 conference:
Egan Peltan
Egan Peltan
Can less weight loss be better weight loss? This morning at ADA, Eli Lilly released data on the Believe Phase 2b study of Bimagrumab in combination with a GLP-1 (Semaglutide) The goal: lose only fat Approach: anorectic + anabolic
@subtlechemism Nope.
Crémieux
Crémieux
A new study of NAION risk with GLP-1RAs just came out. With semaglutide, there was not only no apparent risk, but if anything, there was reduced risk.
Gallery 1
@cmoncanes There's never been good evidence for them. It just doesn't gomd up on closer inspection.
Crémieux
Crémieux
A new study of NAION risk with GLP-1RAs just came out. With semaglutide, there was not only no apparent risk, but if anything, there was reduced risk.
Gallery 1
@AnnieTyzak Eye issues? Never supported with strong evidence.
Crémieux
Crémieux
A new study of NAION risk with GLP-1RAs just came out. With semaglutide, there was not only no apparent risk, but if anything, there was reduced risk.
Gallery 1
@elonmusk And it seems like consumers will have options, too. Multiple other companies are close to their own versions of this product: We live in amazing times!
Crémieux
Crémieux
More companies are jumping in to improve GLP-1-driven weight loss. Scholar Rock is now reporting their own results from using combination tirzepatide and a myostatin inhibitor. At 24 weeks, their results are comparable to semaglutide at 26 weeks with Regeneron's inhibitor:
Gallery 1
@AZchilly Then I'd say you didn't read the article. Here's a helpful thread with human rather than non-human primate results.
Crémieux
Crémieux
More companies are jumping in to improve GLP-1-driven weight loss. Scholar Rock is now reporting their own results from using combination tirzepatide and a myostatin inhibitor. At 24 weeks, their results are comparable to semaglutide at 26 weeks with Regeneron's inhibitor:
Gallery 1
Ottenuto datwitter
8.119
0
Il contenuto di questa pagina è fornito da terze parti. Salvo diversa indicazione, OKX non è l'autore degli articoli citati e non rivendica alcun copyright sui materiali. Il contenuto è fornito solo a scopo informativo e non rappresenta le opinioni di OKX. Non intende essere un'approvazione di alcun tipo e non deve essere considerato un consiglio di investimento o una sollecitazione all'acquisto o alla vendita di asset digitali. Nella misura in cui l'IA generativa viene utilizzata per fornire riepiloghi o altre informazioni, tale contenuto generato dall'IA potrebbe essere impreciso o incoerente. Leggi l'articolo collegato per ulteriori dettagli e informazioni. OKX non è responsabile per i contenuti ospitati su siti di terze parti. Gli holding di asset digitali, tra cui stablecoin e NFT, comportano un elevato grado di rischio e possono fluttuare notevolmente. Dovresti valutare attentamente se effettuare il trading o detenere asset digitali è adatto a te alla luce della tua situazione finanziaria.